脐动脉血PCT、CRP检测在早产儿早期感染中的作用

目的:为进一步提高早产儿重症感染的早期诊断率探讨一种快速、可靠的方法。方法:用LUMITestPCT方法检测我院出生的有感染可能的早产儿的脐动脉血清降钙素原(PCT)。同时检测脐动脉血C反应蛋白(CRP);由新生儿专业的医师对其病情进行观察,在不知道PCT值时做出病情的临床诊断,52例病例分为:重症感染组(n=28)和对照组(n=24)。进行回顾性对比分析。结果:早期开始的早产儿感染与CRP、PCT浓度在出生时的增加相关,差异有极显著性(P<0.001);脐动脉血中,PCT浓度的增加与CRP水平变化呈正相关(r=0.88)。PCT的敏感性(96.4%)和特异性(95.8%)均高于CRP(敏感性75%,特异性91.6%)。结论:PCT可作为早产儿早期感染的早期、快速检测指标,与CRP相比,PCT敏感性、特异性均高。本研究方法对早产儿无创伤。     

两种石油加工残油对制备可纺丝中间相沥青的影响

用常压液相炭化法制备中间相沥青，并用熔融法检验中间相沥青的可纺性，研究了汽油裂解残油和催化裂化重柴油参混比的不同对中间相沥青的制备速率，产率，中间相含量，显微结构以及可纺性的影响，指出最佳配比。     

滋肾通利胶囊治疗泌尿系感染临床研究

目的：观察滋肾通利胶囊治疗泌尿系感染的临床疗效。方法：随机设对照组（120例）和治疗组（136例）,对照组根据药敏选用抗生素口服或静脉滴注,治疗组在上述基础上加用滋肾通利胶囊治疗。2周为1疗程,两个疗程后统计疗效;1年后对复发率进行比较。结果：治疗组总缓解率96.3%,对照组81.7%（P〈0.05）;1年后治疗组复发率4.4%,对照组30.0%（P〈0.01）。结论：滋肾通利胶囊对泌尿系感染有良好作用,长期疗效尤其显著。     

社会能力评定量表的编制及信效度检验

目的：编制社会能力评定量表并检测其信度和效度。方法：在全国五大行政区用社会能力评定量表评估1605例正常人(男性814名，女性791名)，分析量表的信效度。结果：全量表的Cronbach's α系数为0．88-0．92，三个分量表的d系数为0．81～0．88；量表的分半信度为0．76～0．87，量表的重测信度为0．67～0．86，量表评分者信度为0．91～0．97，表明量表具有较好的内部一致性和稳定性；各条目与总分的相关系数0．49-0．80，分量表与总分的相关系数为0．76～0.89，通过因子分析，证实了量表的结构效度；全量表总分和职业能力得分与被试单位提供的实际社会能力评分呈高度相关，与韦氏智商呈中低度相关。结论：量表编制符合心理测量学要求，具有良好的信度和效度。     

真性延髓麻痹并发咽憩室报告1例

真性延髓麻痹主要表现为吞咽困难、构音障碍、饮水呛咳等,严重的影响患者的生活质量.真性延髓麻痹病程超过2个月,尤其身体消瘦者,常发生咽憩室,主要表现为食物返流.因为真性延髓麻痹是下运动神经元损伤,可以引起咽肌肌力和肌张力低下、肌萎缩,因此使梨状隐窝加深而形成咽憩室,在临床上报道少见.     

血半胱氨酸蛋白酶抑制剂C水平对急性脑血管病患者早期肾损害的诊断价值

目的探讨急性脑血管病患者早期肾损害的机制及早期监测指标。方法对194例急性脑血管病患者(包括脑梗死129例,脑出血65例)及60例正常对照者同时测定血半胱氨酸蛋白酶抑制剂C(Cys-C)和血肌酐(SCr)浓度,对其中血Cys-c浓度增高但SCr浓度正常的48例急性脑血管病肾早期损害患者用甘露醇治疗,并检测治疗前后血Cys-c浓度。结果在早期肾损害组,血Cys-c浓度明显高于对照组(P<0.001),而SCr浓度2组无显著性差异(P>0.05)。48例急性脑血管病肾早期损害者经甘露醇治疗后,血Cys-c浓度较治疗前明显降低(P<0.001)。结论血清Cys-c测定有助于早期发现肾功能损害,治疗脑血管病的同时应注意监测肾功能。     

38例视网膜母细胞瘤的临床和误诊分析

目的 探讨视网膜母细胞瘤（retinoblastoma，RB）的临床特征、病理分类和误诊原因，尽可能减少错误的临床诊治。方法 对我科于1999-2004年间收集的38例临床诊断为视网膜母细胞瘤（retinoblastoma，RB）的病例资料进行回顾性分析。结果在38例疑似病例中，34例病理诊断为视网膜母细胞瘤，4例为Coats病。结论掌握相关的影像学知识和综合分析疑难病例的临床资料将有助于视网膜母细胞瘤的正确诊断和处理。     

放射线联合p53基因及内皮抑素治疗小鼠前列腺癌皮下移植瘤

Objective To test the hypothesis that p53 gene therapy combined with endostatin can enhance tumor response to radiation therapy of RM-1 mouse xenograft prostate cancer and to investigate its mechanism. Methods A mouse prostate cancer model was established. Then mice with xenograft tumor were randomly divided into group A (control), B (radiation), C (radiation and rAdp53), D (radiation and rh-endostatin) and E (radiation and rAdp53 and rh-endostatin). On day 1, rAdp53 was injected intra-tumorously with 1 × 1010 vp per animal to group C and E. From day 1 to 14, rh-endostatin was given 15 mg/kg intraperitoneally daily to group D and E. On day 4 single fraction of 15 Gy was given to tumors in groups B, C, D and E. Normal saline was injected intra-tumorously or intraperitoneaUy accordingly as control. No treatment was done to group A. Tumor volume was measured daily. Samples were collected on Days 5, 10 and 15. Ki67, CD31, p53 and VEGF were detected by means of immunohistochemistry. Results (1) Radiation alone, radiation combined with intra-tumorous injection of Adp53 and/or intraperitoneal injection of rh-endostatin resulted in tumor growth arrest of RM-1 cells in vivo (P = 0.000). Radiation combined with both rAdp53 and rh-endostatin was the most effective treatment (P < 0.05). (2) All the four treatment groups had a decreased expression of mutant type P53 (P = 0.000). The expression of Ki67 in groups B and C were equal (P 0.05) and increasing (P = 0.000), respectively. Group D had a up-down-up curve (P < 0.05), but group E had a up-down one. On day 5 the expresion of VEGF in group E was the lowest (P < 0.05). An increased expression of MVD compared with the control was shown, and MVD in groups C, D and E were always higher than that in the control (P < 0.05). Conclusions The limitation of radiotherapy could be overcome by combination with beth p53 gene therapy and endostatin on the growth of mouse prostate cancer cell. Radiation, rAdp53 and endostatin have their own role but they can be interacted with each other.     

RNA干扰基因敲除MAGE-1在恶性胶质瘤U87细胞中的初步研究

目的：通过构建抑制MAGE-1的短片段双链核糖核酸（siRNA）表达载体，鉴定其在人恶性胶质瘤细胞系U87细胞中对MAGE．1基因表达的干涉作用。方法：化学合成2对编码短发夹RNA序列的靶向MAGE—1基因寡核苷酸链，克隆至经BglⅡ、HindⅢ双酶切的pSUPER载体上，重组构建核糖核酸干扰（RNAi）质粒载体。利用RT-PCR、流式细胞术和荧光显微镜，检测经稳定转染后胶质瘤U87细胞中MAGE-1的表达，以了解siRNA的干涉效果。结果：重组构建的pSUPER—MAGE—1载体经双酶切、电泳及插入基因片段序列分析，表明寡核苷酸链成功地插入至预计位点，且序列与预期完全一致。稳定转染后G418筛选出的U87多克隆细胞MAGE-1的表达经RT—PCR、流式细胞术和荧光显微镜检测，2对siRNA均有较明显的干扰作用。结论：载体的成功构建并能对U87细胞中的MAGE—1分子进行RNAi，为进一步研究MAGE—1在肿瘤中的作用，分析基因功能，展开肿瘤基因治疗奠定了基础。     

Contribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients

Abstract:  The risks of developing malignant melanoma (MM) include ultraviolet irradiation and genetic factors. To examine the contribution of rare and common variation within known MM genes in sporadic US MM patients, coding regions of known MM susceptibility genes [cyclin-dependent kinase inhibitor 2A ( CDKN2A ), cyclin-dependent kinase 4, melanocortin 1 receptor ( MC1R ) and tyrosinase ( TYR )] were resequenced in 109–135 MM cases. The significance of variants was examined by comparing their frequencies in 390 cancer-free controls. Potential deleterious mutations in CDKN2A were found in two patients and two others had variants of unknown significance. Cases were more likely than controls to harbour the MC1R 'R' variants known or predicted to alter its function ( P  = 0.002), particularly the R160W variant ( P  = 0.0035). The associated TYR R402Q variant (rs1126809*A) was found in 29% of cases, similar to what has been described previously. One MM patient with a family history of MM, who had developed other skin cancers, was homozygous for a novel TYR variant (P406L) of unknown significance. Hence, rare variants in TYR may be important risk factors for skin cancer.